CXCL12 and central nervous system cancer: Currently, two clinical trials (NCT01977677, NCT01339039) are ongoing evaluating the potential and applicability of the SDF-1 inhibitor Plerixafor (AMD3100, Mozobil®, #05379530, Sanofi Genzyme, Cambridge, MA, USA) in gliomas [144,159].